Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819052 | 0.93 | KCNK3 (0.36) | KCNK3KCNK9SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2819041 | 0.93 | LMNA (0.39) | SMN1; SMN2LMNAL3MBTL1PDE4DMAPT | |
| SCHEMBL2819037 | 0.93 | LMNA (0.39) | SMN1; SMN2LMNAL3MBTL1PDE4DMAPT | |
| SCHEMBL2820851 | 0.91 | LMNA (0.36) | KCNK3KCNK9SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2820866 | 0.89 | MAOB (0.37) | SMN1; SMN2LMNAL3MBTL1MAPTCYP1A2 | |
| SCHEMBL2823839 | 0.89 | MAOB (0.37) | SMN1; SMN2LMNAL3MBTL1MAPTCYP1A2 | |
| SCHEMBL2820681 | 0.89 | LMNA (0.37) | KCNK3KCNK9SMN1; SMN2LMNAL3MBTL1 | |
| SCHEMBL2825547 | 0.89 | LMNA (0.38) | SMN1; SMN2LMNAL3MBTL1PDE4DMAPT | |
| SCHEMBL2825545 | 0.89 | LMNA (0.38) | SMN1; SMN2LMNAL3MBTL1PDE4DMAPT | |
| SCHEMBL2821638 | 0.88 | ALDH1A1 (0.40) | SMN1; SMN2LMNAL3MBTL1PDE4DMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | claimed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | claimed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-8349846-B2 | Fused pyrimidine derivatives as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2013-01-08 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-18 | — | — | US | disclosed |
| WO-2009109987-A2 | FUSED PYRIMIDINE DERIVATIVES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292254-A1 | Fused Pyrimidine Derivatives as Trpv3 Modulators | TRPV3, TRPV1, TRPV5 | KCNK3 121/4885KCNK9 483/4885SMN1; SMN2 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.